Spire Wealth Management’s iBio IBIO Stock Holding History

Spire Wealth Management’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2	Closed	-$2K	–	2609
2021 Q2	$2K	Buy	+2	New	+$1.46K	﹤0.01%	2480

Other funds holding IBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Spire Wealth Management's IBIO Position: Q3 2021 in Review

Spire Wealth Management sold out of iBio (IBIO) in Q3 2021, closing a stake of 2 shares — an estimated $2K sold.

Spire Wealth Management first reported a position in IBIO in Q2 2021 and held it in 1 quarter. The position peaked at $2K in Q2 2021. 85 funds tracked by Wall St. Rank hold IBIO as of Q3 2021.

Spire Wealth Management reported no remaining iBio position as of Q3 2021 after selling out during the quarter.
Spire Wealth Management sold 2 iBio shares in Q3 2021, an estimated $2K.
Spire Wealth Management first reported a position in iBio in Q2 2021 and held it in 1 quarter.
Spire Wealth Management's iBio position peaked at $2K in Q2 2021.
85 funds tracked by Wall St. Rank held iBio as of Q3 2021.

Based on Spire Wealth Management's 13F filing for Q3 2021, filed 22 Oct 2021.